NOMURA HOLDINGS INC-SPON ADR (NMR) Stock Fundamental Analysis
NYSE:NMR - New York Stock Exchange, Inc. - US65535H2085 - ADR - Currency: USD
Taking everything into account, NMR scores 3 out of 10 in our fundamental rating. NMR was compared to 233 industry peers in the Capital Markets industry. NMR may be in some trouble as it scores bad on both profitability and health. NMR is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
NMR had positive earnings in the past year.
NMR had a negative operating cash flow in the past year.
In the past 5 years NMR has always been profitable.
The reported operating cash flow has been mixed in the past 5 years: NMR reported negative operating cash flow in multiple years.
1.2 Ratios
Looking at the Return On Assets, with a value of 0.60%, NMR is doing worse than 69.10% of the companies in the same industry.
NMR has a Return On Equity of 9.82%. This is comparable to the rest of the industry: NMR outperforms 58.37% of its industry peers.
NMR has a worse Return On Invested Capital (0.62%) than 72.10% of its industry peers.
The Average Return On Invested Capital over the past 3 years for NMR is significantly below the industry average of 7.86%.
The 3 year average ROIC (0.41%) for NMR is below the current ROIC(0.62%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.6% | ||
| ROE | 9.82% | ||
| ROIC | 0.62% |
ROA(3y)0.36%
ROA(5y)0.36%
ROE(3y)5.9%
ROE(5y)5.66%
ROIC(3y)0.41%
ROIC(5y)0.41%
1.3 Margins
NMR has a worse Profit Margin (7.19%) than 65.24% of its industry peers.
In the last couple of years the Profit Margin of NMR has declined.
With a Operating Margin value of 9.96%, NMR is not doing good in the industry: 70.82% of the companies in the same industry are doing better.
In the last couple of years the Operating Margin of NMR has declined.
NMR has a worse Gross Margin (39.95%) than 65.24% of its industry peers.
NMR's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.96% | ||
| PM (TTM) | 7.19% | ||
| GM | 39.95% |
OM growth 3Y-11.17%
OM growth 5Y-4.76%
PM growth 3Y-7.1%
PM growth 5Y-8.33%
GM growth 3Y-22.42%
GM growth 5Y-9.54%
2. Health
2.1 Basic Checks
The number of shares outstanding for NMR has been reduced compared to 1 year ago.
The number of shares outstanding for NMR has been reduced compared to 5 years ago.
The debt/assets ratio for NMR has been reduced compared to a year ago.
2.2 Solvency
NMR has an Altman-Z score of -0.25. This is a bad value and indicates that NMR is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of NMR (-0.25) is worse than 80.26% of its industry peers.
A Debt/Equity ratio of 10.44 is on the high side and indicates that NMR has dependencies on debt financing.
NMR has a Debt to Equity ratio of 10.44. This is amonst the worse of the industry: NMR underperforms 89.70% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 10.44 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.25 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
NMR has a Current Ratio of 0.23. This is a bad value and indicates that NMR is not financially healthy enough and could expect problems in meeting its short term obligations.
NMR has a worse Current ratio (0.23) than 87.98% of its industry peers.
A Quick Ratio of 0.23 indicates that NMR may have some problems paying its short term obligations.
With a Quick ratio value of 0.23, NMR is not doing good in the industry: 87.98% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.23 | ||
| Quick Ratio | 0.23 |
3. Growth
3.1 Past
NMR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 96.52%, which is quite impressive.
Measured over the past years, NMR shows a quite strong growth in Earnings Per Share. The EPS has been growing by 10.96% on average per year.
NMR shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 13.94%.
Measured over the past years, NMR shows a quite strong growth in Revenue. The Revenue has been growing by 19.39% on average per year.
EPS 1Y (TTM)96.52%
EPS 3Y34.65%
EPS 5Y10.96%
EPS Q2Q%13.06%
Revenue 1Y (TTM)13.94%
Revenue growth 3Y43.77%
Revenue growth 5Y19.39%
Sales Q2Q%6.19%
3.2 Future
Based on estimates for the next years, NMR will show a decrease in Earnings Per Share. The EPS will decrease by -4.35% on average per year.
The Revenue is expected to decrease by -8.82% on average over the next years.
EPS Next Y-4.32%
EPS Next 2Y-4.35%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-3.69%
Revenue Next 2Y-1.64%
Revenue Next 3Y-8.82%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 8.00, the valuation of NMR can be described as very reasonable.
Based on the Price/Earnings ratio, NMR is valued cheaply inside the industry as 85.41% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of NMR to the average of the S&P500 Index (27.50), we can say NMR is valued rather cheaply.
Based on the Price/Forward Earnings ratio of 8.35, the valuation of NMR can be described as reasonable.
NMR's Price/Forward Earnings ratio is rather cheap when compared to the industry. NMR is cheaper than 86.70% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 36.44, NMR is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8 | ||
| Fwd PE | 8.35 |
4.2 Price Multiples
NMR's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. NMR is cheaper than 70.82% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 22.04 |
4.3 Compensation for Growth
A cheap valuation may be justified as NMR's earnings are expected to decrease with -4.35% in the coming years.
PEG (NY)N/A
PEG (5Y)0.73
EPS Next 2Y-4.35%
EPS Next 3YN/A
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 5.06%, NMR is a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 7.76, NMR has a dividend in line with its industry peers.
NMR's Dividend Yield is rather good when compared to the S&P500 average which is at 2.35.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.06% |
5.2 History
The dividend of NMR is nicely growing with an annual growth rate of 15.59%!
NMR has paid a dividend for at least 10 years, which is a reliable track record.
The dividend of NMR decreased in the last 3 years.
Dividend Growth(5Y)15.59%
Div Incr Years2
Div Non Decr Years2
5.3 Sustainability
NMR pays out 33.03% of its income as dividend. This is a sustainable payout ratio.
DP33.03%
EPS Next 2Y-4.35%
EPS Next 3YN/A
6.32
-0.03 (-0.47%)
Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)
Earnings (Next)
Inst Owners38.49%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap18.82B
Analysts69.23
Price Target7.24 (14.56%)
Short Float %0.05%
Short Ratio2.65
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.06% |
Yearly Dividend0.27
Dividend Growth(5Y)15.59%
DP33.03%
Div Incr Years2
Div Non Decr Years2
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)23.99%
Min EPS beat(2)-10.21%
Max EPS beat(2)58.19%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.01%
PT rev (3m)-3.33%
EPS NQ rev (1m)0.01%
EPS NQ rev (3m)-65.23%
EPS NY rev (1m)0.01%
EPS NY rev (3m)4.74%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.2%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8 | ||
| Fwd PE | 8.35 | ||
| P/S | 0.59 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.81 | ||
| P/tB | 0.81 | ||
| EV/EBITDA | 22.04 |
EPS(TTM)0.79
EY12.5%
EPS(NY)0.76
Fwd EY11.98%
FCF(TTM)-3.49
FCFYN/A
OCF(TTM)-1.53
OCFYN/A
SpS10.69
BVpS7.83
TBVpS7.83
PEG (NY)N/A
PEG (5Y)0.73
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.6% | ||
| ROE | 9.82% | ||
| ROCE | 1.58% | ||
| ROIC | 0.62% | ||
| ROICexc | 0.68% | ||
| ROICexgc | 0.69% | ||
| OM | 9.96% | ||
| PM (TTM) | 7.19% | ||
| GM | 39.95% | ||
| FCFM | N/A |
ROA(3y)0.36%
ROA(5y)0.36%
ROE(3y)5.9%
ROE(5y)5.66%
ROIC(3y)0.41%
ROIC(5y)0.41%
ROICexc(3y)0.45%
ROICexc(5y)0.45%
ROICexgc(3y)0.46%
ROICexgc(5y)0.46%
ROCE(3y)1.07%
ROCE(5y)1.07%
ROICexcg growth 3Y16.49%
ROICexcg growth 5Y7.83%
ROICexc growth 3Y15.92%
ROICexc growth 5Y7.53%
OM growth 3Y-11.17%
OM growth 5Y-4.76%
PM growth 3Y-7.1%
PM growth 5Y-8.33%
GM growth 3Y-22.42%
GM growth 5Y-9.54%
F-Score6
Asset Turnover0.08
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 10.44 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 67.92 | ||
| Cap/Depr | 1410.99% | ||
| Cap/Sales | 18.37% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.23 | ||
| Quick Ratio | 0.23 | ||
| Altman-Z | -0.25 |
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)988.49%
Cap/Depr(5y)668.06%
Cap/Sales(3y)14.69%
Cap/Sales(5y)11.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)96.52%
EPS 3Y34.65%
EPS 5Y10.96%
EPS Q2Q%13.06%
EPS Next Y-4.32%
EPS Next 2Y-4.35%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)13.94%
Revenue growth 3Y43.77%
Revenue growth 5Y19.39%
Sales Q2Q%6.19%
Revenue Next Year-3.69%
Revenue Next 2Y-1.64%
Revenue Next 3Y-8.82%
Revenue Next 5YN/A
EBIT growth 1Y72.34%
EBIT growth 3Y27.7%
EBIT growth 5Y13.71%
EBIT Next Year20481.7%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-122.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-883.38%
OCF growth 3YN/A
OCF growth 5YN/A